Aspirin: Primary Prevention of Cardiovascular Disease and Cancer
%20compared%20with%20no%20aspirin%20in%20the%20primary%20prevention%20of%20cardiovascular%20disease%20and%20cancer.jpeg)
Cardiovascular disease (CVD) and cancer are the leading causes of morbidity and mortality worldwide, representing 24 and 13 percent of all deaths, respectively. Aspirin produces significant reductions in CVD morbidity and mortality among survivors of a wide range of occlusive CVD events, including subsequent coronary heart disease, especially myocardial infarction (MI) and stroke. In secondary prevention, the absolute benefits of occlusive events are far greater than the absolute risks of major bleeding. In primary prevention, however, among apparently healthy people, the benefit-to-harm ratio is less clear. Although the benefits of Aspirin on CVD have been known for decades, more recent evidence from randomized trials has suggested a benefit on colorectal cancer. These findings may impact the threshold for the prescription of aspirin by health care professionals and the wishes of healthy people considering aspirin use. Possible Benefit's All-cause mortality or cardiovascul...